Association of polypharmacy with all-cause mortality and adverse events among elderly colorectal cancer survivors.
Dong-Woo ChoiHyejung KangHyun-Soo ZhangHoyol JhangWonjeong JeongSohee ParkPublished in: Cancer (2023)
The risk of inappropriate drug exposure in older colorectal cancer (CRC) survivors after the initial cancer treatment has not been well studied. Polypharmacy was associated with adverse outcomes, including all-cause mortality, hospitalization, and emergency room visits among older CRC survivors and it was particularly associated with those who were 65 to 75 years and those with low risk of frailty. When prescribing drugs, physicians should be mindful of finding a balance between adequate treatment of diseases and avoiding adverse drug effects in survivors of CRC.